Oncology Diagnostics Panel Session
The Value and Drawbacks of an Integrated Pharma/Diagnostics Model dives into how Roche has revolutionized an integrated model of designing and developing therapeutics and diagnostics under one roof. Read how our panelists view this approach and what advantages and disadvantages are.
- Shailesh Maingi – Founder and CEO, Kineticos
- Eric Mayer – CEO, EDP Biotech
- Sandra Dunn – CEO, Phoenix Molecular
- Brian Kelly – Global Director, Diagnostic Partnering, Thermo Fisher
- Part 1 – Can Diagnostics Keep Up with Pharma
- Part 2 – Making Up for Unfavorable Reimbursement
- Part 3 – The Impact of I/O on Oncology Diagnostics
- Part 4 – A Path to Success in Diagnostics
Subscribe to Kineticos to receive weekly emails containing insightful content.